Agentix Corp.

AI-generated fair value estimate for this company.

Method: Risk-adjusted NPV (rNPV) of pipeline, net of negative working capital, discounted for near-term dilution: AGTX-2004 (IND cleared, Phase 1-ready CB1 antagonist for obesity/T2D) valued at $200M potential deal value x 10% probability of reaching licensing, 3-year horizon, 20% discount rate (~$11.57M); AGTX-2003 (preclinical CB1 inverse agonist) at $100M deal value x 4% probability, 4-year horizon, 20% discount (~$1.93M); less $3.6M net current liabilities against $771 cash; remaining ~$9.9M haircut to 15% retained value to reflect severe near-term equity financing need given going-concern doubt; divided by 40.07M shares outstanding.

Reasoning: Agentix has essentially no cash ($771) against $3.6M of current liabilities and explicit going-concern doubt in its 10-K, so its equity value is best captured as a deeply-discounted call option on its two preclinical/Phase-1 CB1 receptor assets rather than a conventional FCF-based DCF, which is undefined given no revenue or near-term cash flow.